Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Q10

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Q10. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-006105-40 Sponsor Protocol Number: COQ10INF Start Date*: 2006-06-05
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
    Full Title: TREATMENT OF IDIOPATHIC ASTHENOZOOSPERMIE WITH COENZYME Q10. A DOUBLE BLIND CONTROLLED STUDY
    Medical condition: IDIOPATHIC ASTHENOZOOSPERMIA
    Disease: Version SOC Term Classification Code Term Level
    6.1 10013358 HLT
    Population Age: Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002455-41 Sponsor Protocol Number: Start Date*: 2006-02-15
    Sponsor Name:Karolinska Institutet
    Full Title: Clinical, morphological and biochemical effects of antioxidant treatment of patients with chronic hepatitis C.
    Medical condition: Chronic hepatitis C with moderate to severe liver damage. The patients should not be suitable for standard medical treatment or refuse standard medical treatment for personal reasons.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002369-29 Sponsor Protocol Number: T08 Start Date*: 2008-08-20
    Sponsor Name:MSE Pharmazeutika GmbH
    Full Title: Randomized, double-blind study of nanoquinone versus placebo in patients with tinnitus aurium and low baseline blood levels of Q10
    Medical condition: Patients with tinnitus aurium and low blood levels of Q10
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005982-18 Sponsor Protocol Number: COQ10-FM-2012 Start Date*: 2013-01-09
    Sponsor Name:Mónica Saldaña Valderas
    Full Title: Randomized, placebo-controlled and double blind clinical trial to assess the efficacy of ubidecarenone in patients diagnosed with fibromyalgia
    Medical condition: Fibromyalgia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10048439 Fibromyalgia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004220-13 Sponsor Protocol Number: Q-301 Start Date*: 2005-06-08
    Sponsor Name:Q-Develop AB/co Freddie Norberg
    Full Title: Treatment of vulvar vestibulitis by an antioxidant cream: a double-blind, placebo-controlled, parallel group multi-center study
    Medical condition: Vulvar vestibulitis, a recently discovered disease, which mainly affects young women. The symptoms are severe vaginal pain.
    Disease: Version SOC Term Classification Code Term Level
    10047780 PT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005961-16 Sponsor Protocol Number: QVID-001 Start Date*: 2021-02-05
    Sponsor Name:Lars Jørgen Østergaard
    Full Title: Coenzyme Q10 as treatment for Long Term COVID-19 (The QVID study)
    Medical condition: Long Term COVID-19 illness
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-000574-40 Sponsor Protocol Number: PSP-CoQ10 Start Date*: 2006-04-24
    Sponsor Name:Kompetenznetz Parkinson e.V.
    Full Title: Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon®
    Medical condition: PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 10...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002960-27 Sponsor Protocol Number: P-6708H Start Date*: 2007-07-23
    Sponsor Name:Pharma Nord ApS
    Full Title: Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on Symptoms, Biomarker status (BNP) and long-term Outcome (hospitalisation/mort...
    Medical condition: Chronic heart failure for more than 6 weeks, in NYHA class III or IV. Age>18 years; males and females. Optimal medical treatment of heart failure according to the investigators opinion.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-001198-18 Sponsor Protocol Number: ITS2006-1 Start Date*: 2006-05-30
    Sponsor Name:Sligo General Hospital
    Full Title: Improving Tolerability of Statins
    Medical condition: Subjects for whom statin intake is a necessary therapeutic intervention i.e diabetics, dyslipidemics and patients with ischaemic heart disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005675-15 Sponsor Protocol Number: DIL-UBI-DEX-CLOII/2003/003/PT Start Date*: 2008-10-08
    Sponsor Name:Tecnimede, Sociedade Técnico-Medicinal S.A.
    Full Title: Randomized, multicenter, placebo-controlled, single blind study to assess the efficacy and tolerability of a combination of a cream containing ubidecarenone, dexpanthenol and chlorohexidine and a p...
    Medical condition: Cronic Anal fissure (CAF) The underlying pathogenesis of chronic anal fissure involves initial local trauma (generally caused by hard stools), resulting in a wound, internal anal sphincter spasm an...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10071195 Chronic anal fissure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-002471-27 Sponsor Protocol Number: 2008-15 Start Date*: 2008-07-22
    Sponsor Name:Assistance Publique Hopitaux de marseille
    Full Title: Traitement de la Progéria de Hutchinson-Gilford par l’association de pravastatine (Vasten®) et d’acide zolédronique (Zométa®)
    Medical condition: Progéria de Hutchinson-Gilford et syndromes progéroides
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005021-76 Sponsor Protocol Number: OPBGC&RS_12_003 Start Date*: 2013-01-31
    Sponsor Name:EDISON PHARMACEUTICALS INC.
    Full Title: A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children with Rett Syndrome
    Medical condition: Rett Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10021605 Inborn errors of metabolism HLGT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003293-25 Sponsor Protocol Number: DIM05 Start Date*: 2007-11-20
    Sponsor Name:Medivation, Inc.
    Full Title: A MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE
    Medical condition: Huntington's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020469 Huntington's chorea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004364-20 Sponsor Protocol Number: MK-3475-598 Start Date*: 2017-12-04
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumo...
    Medical condition: Metastatic programmed cell deathligand 1 (PD-L1) positive (TPS ≥50%) non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) LV (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003028-19 Sponsor Protocol Number: PS_KSS_001_2019 Start Date*: 2019-10-30
    Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
    Full Title: Clinical-instrumental definition of the phenotypic spectrum, response to treatment and natural history in Pearson and Kearns-Sayre syndrome
    Medical condition: Pearson and Kearns-Sayre syndrome.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10058799 Mitochondrial encephalomyopathy PT
    20.1 10010331 - Congenital, familial and genetic disorders 10058799 Mitochondrial encephalomyopathy PT
    20.1 10010331 - Congenital, familial and genetic disorders 10051403 Mitochondrial DNA deletion PT
    20.1 10010331 - Congenital, familial and genetic disorders 10051403 Mitochondrial DNA deletion PT
    20.0 10010331 - Congenital, familial and genetic disorders 10074070 Mitochondrial encephalopathy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002846-33 Sponsor Protocol Number: KL13332020-104A Start Date*: 2022-10-13
    Sponsor Name:Abliva AB
    Full Title: An interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose, adaptive study of the efficacy of KL1333 in adult patients with primary mitochondrial disease
    Medical condition: Adult patients with primary mitochondrial disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10052637 Genetic mitochondrial abnormalities NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005079-26 Sponsor Protocol Number: 1370.2 Start Date*: 2016-07-20
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: ELUXA 2: An international, randomised, multi-centre, active controlled, open-label Phase III study evaluating the efficacy of BI 1482694 versus standard platinum doublet chemotherapy in patients wi...
    Medical condition: Locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003331-23 Sponsor Protocol Number: LA29-0207 Start Date*: 2008-11-20
    Sponsor Name:ApoPharma Inc.
    Full Title: A six-month double-blind, randomized, placebo-controlled study investigating the safety and tolerability of deferiprone in participants with Friedreich's ataxia
    Medical condition: Friedreich's Ataxia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017374 Friedreich's ataxia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FR (Completed) IT (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004959-30 Sponsor Protocol Number: 1373.3 Start Date*: 2016-02-25
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomised, double-blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in patients with...
    Medical condition: Non small cell lung cancer stage III after concurrent chemoradiation therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NO (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001477-41 Sponsor Protocol Number: 1373.1 Start Date*: 2015-11-19
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: A randomised, double blind phase I/II trial to investigate efficacy, immunogenicity and safety of intradermally administered BI 1361849 (CV9202) plus afatinib versus placebo plus afatinib as first-...
    Medical condition: Advanced non-small cell lung cancer (adenocarcinoma) stage IV.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:02:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA